David Weingeist
Scientific Director, Oncology Diagnostics Leader Johnson & Johnson
Seminars
Wednesday 4th February 2026
Underpinning the Value of Urine for Predictive & Monitoring Biomarkers in Bladder Cancer
2:20 pm
- Urine-based LBx for patient selection in bladder cancer
- Implementation of urine-based LBx in clinical practice as a non-invasive testing option
- Future applications of urine-based LBx, including MRD and patient monitoring
